



Ref: Syn/CS/SE/IP/2026-27/Oct/08

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.

T +91 80 6891 9191

CIN: L85110KA1993PLC014937

www.syngeneintl.com

October 27, 2026

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter and half year ended September 30, 2026. The Company will use this presentation for any meeting scheduled with analysts or institutional investors.

The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

CHETHAN
N
YOGESH
Digitally signed
by CHETHAN
YOGESH
Date: 2026.10.27
21:25:49 +05'30'

Chethan Yogesh
Company Secretary and Compliance Officer

Enclosed: Investor Presentation

Investor Presentation

October 2026



Safe harbour



Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the Company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.



Contents

1	Q2 FY27 Highlights
2	Syngene – Putting Science to Work
3	Syngene strengths
4	Financials
5	Shareholding and Share Information



1

Q2 FY27 Highlights



Q2 FY27 performance

Operating Highlights

- **Integrated Drug Discovery (IDD):** Syngene strengthened its integrated drug discovery offering by bringing Chemistry, Biology and Biotherapeutics under unified leadership of Chief Scientific Officer Dr. Jayashree Aiyar
- **Bayview Biologics Facility:** Syngene signed first manufacturing agreement for the Bayview facility with a large pharmaceutical customer – an important milestone in its large-molecule manufacturing journey. Process development is scheduled to begin in India this year, followed by drug-substance manufacturing at Bayview next year, strengthening Syngene's integrated India-U.S. delivery model and dual-continent supply capabilities
- **Biologics Manufacturing:** Secured additional manufacturing contracts, including an agreement to supply clinical materials from its Bengaluru biologics facility (Unit 3). These engagements demonstrate encouraging customer traction and support the development of a broader manufacturing pipeline
- **Capability Enhancement:** Commissioned a Clinical Translational Sciences laboratory in Bengaluru, integrating clinical biomarker development and validation, biobanking, patient stratification, precision medicine and bioanalytical capabilities. The facility strengthens connectivity across discovery-development continuum. Syngene also expanded its digital capabilities through ChemVoyager, automated analytical systems and end-to-end sample tracking, enabling more connected, efficient and data-driven research workflows
- **Cost Competitiveness:** Continued implementing cost-optimization initiatives to improve operational efficiency and competitiveness. Manpower-related optimization has been completed, while other initiatives remain underway, with benefits expected over the coming quarters

Q2 FY27 Financial Highlights

	Q2FY27	H1FY27
Revenue from Operations	Rs 833 Cr +13% Q-o-Q -9% Y-o-Y	Rs 1,569 Cr -12% Y-o-Y
Operating EBITDA margin	18% ¹ 12% in Q1FY27 22% in Q2 FY26	15% 23% in H1FY26
PAT, before exceptional items ²	Rs. 38 Cr Rs. 1 Cr in Q1FY27 Rs. 67 Cr in Q2FY26	Rs. 39 Cr Rs. 154 Cr in H1FY26
PAT, after exceptional items	Rs 32 Cr Rs. 9 Cr Loss in Q1FY27 Rs. 67 Cr in Q2FY26	Rs 23 Cr Rs. 154 Cr in H1FY26

¹Operating EBITDA margin stood at 18%, in line with expectations, reflecting lower revenues and forex hedge losses. Adjusted for the forex hedge loss, the operating EBITDA margin for the quarter would be in the mid-20s range.

²Excludes exceptional expenses related to employee termination benefits, net of tax: Rs 6 Cr for Q2 FY27 and Rs 16 Cr for H1 FY27

2

Syngene – Putting Science to Work

Syngene



Partner in innovation: #Putting Science to Work

Who we are and what we do

We aim to be a world class partner delivering innovative scientific solutions for clients



We offer integrated solutions across research, development and manufacturing



Sector expertise include pharmaceuticals, biotech, nutrition, animal health, consumer goods and specialty chemicals




Our team includes more than ~5,700+ scientists out of total 8,300+ headcount, operating across 4 global state-of-the-art campuses located in India's leading life science hubs: Bangalore, Mangalore, Hyderabad and USA (Baltimore)



Established track record in discovery research and development/ manufacturing for small and large molecules

Our journey so far



Key facts and figures



~400
active clients



16 out of top **20**
pharma companies are
clients



400+
patents
held with clients



World class infrastructure
International presence with global
campuses across Bangalore, Hyderabad
and Mangalore in India and Baltimore in
USA qualified to meet international
standards



Rs. 3,739 Cr
FY26 Revenue from
operations



Rs. 380 Cr*
FY26 PAT



8,373 headcount
including **5,778**
talented scientists



92%
energy from
renewable sources




Syngene – one of the largest integrated CRDMO players in India

One-stop platform for integrated drug discovery, development and manufacturing across modalities

Expanding capacity

(in Million sq. ft.)




More than tripled the infrastructure that is qualified to meet international standards

- Expanded laboratory capacity in Bangalore and Hyderabad
- Expanded to Mangalore for commercial API manufacturing
- Acquired land in Hyderabad for long term growth in research business
- Acquired multi-modal biologics facility from Stelis Biopharma Ltd
- Acquired first biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC
- US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC accredited and GLP certified facilities

Building capabilities for future

(#)




Over 2.5x employees from FY16 comprising talented scientists

- ~5,700+ scientists comprising PhDs, MS
- Skills and experience to become trusted thought partner in cutting-edge research
- Scientific prowess across modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs
- Proven success in delivering integrated CMC programs and clinical candidates

Building partnerships

(#)



Over 50% increase in active clients

16 out of top 20 pharma companies are clients

- Expanded partnerships with big pharma and emerging biopharma
- Expanded into commercial manufacturing in Biologics with Zoetis
- Enhanced BD presence across key value clusters including US and Europe
- 25-year strategic partnership with BMS – established BBRC, India's first and largest dedicated R&D center

3-pronged growth strategy across diversified platform

Research Services (CRO)

Discovery Services



Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs

SynVent - proprietary platform for Integrated Drug Discovery

SARchitect- proprietary platform for data visualization and analysis. Enables collaboration between scientific experts across geographies

Dedicated R&D Centers



Ring-fenced infrastructure for exclusive operations for an individual client

Dedicated multi-disciplinary team of scientists

Access to entire Syngene ecosystem for specialist research and development operations

T&CR



Comprehensive research services through trials conducted on both healthy volunteers and patients

- Human Pharmacology Unit (Phase I/BE studies)
- Clinical Trial Services – full solution provider for conducting global trials
- Translational services- a continuum from preclinical to clinical trials
- Regulated bioanalysis for large and small molecules
- Central Laboratory

Large Molecule CDMO



Process development

Manufacturing of large molecules for clinical/commercial supplies

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant facilities

State-of-the art Biologics manufacturing facilities with international presence

Small Molecule CDMO



Drug substance and drug product development

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing of small molecules for commercial supplies

State-of-the art API manufacturing facility

Our Strategy



Research Services

Provide an integrated end-to-end therapeutic discovery services Encompassing drug discovery, pre-clinical and clinical development capabilities across technologies, platforms, disciplines, disease areas and therapeutic modalities.



Development and Manufacturing Services – Large Molecules

Implement a comprehensive strategy for biologics development and manufacturing, establishing a seamless, one-stop-shop capability that covers everything from drug discovery to commercial production.



Development and Manufacturing Services – Small Molecules

Utilize existing Chemistry, Manufacturing, and Controls (CMC) capabilities and commercial manufacturing, while also developing innovative technologies, to establish a fully integrated, cutting-edge small molecule development and manufacturing service provider



Operational Excellence

Drive operational excellence through improved reliability, speed and efficiency to enhance customer delivery and satisfaction.



People

Build a future ready, high-performance organization by nurturing leadership at all levels, fostering holistic employee well-being, and driving a culture of continuous growth and innovation



Environmental, Social and Governance (ESG)

Syngene is committed to responsible and sustainable growth, ensuring that its ESG standards meet the evolving expectations of clients, investors, and stakeholders. Our ESG strategy is a key enabler of long-term value creation, embedding environmental stewardship, social responsibility, and robust governance across all aspects of our operations

3

Syngene strengths



Syngene strengths

A global scale CRDMO player

- Integrated Drug Discovery, Development and Manufacturing service provider
- Small and large molecules, ADCs, oligonucleotides
- Listed on Indian Stock Exchanges (NSE and BSE)



Solutions through innovation

- IP fully assigned to clients
- Track record of data management and security
- Over 400+ patent filings by clients recognizing Syngene scientists



Quality matters

- Fully digitized quality organization
- Strong compliance track record with global regulators
- US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC accredited and GLP certified facilities
- 85 client and regulator audits in the last financial year



Science in our DNA

- Global presence : India life science hubs: Bangalore, Mangalore and Hyderabad & Baltimore, USA
- ~5700+ qualified scientists including ~500 PhDs (8,300+ total headcount)
- Resilient supply chain management
- ~3 Mn sq. ft world-class R&D and manufacturing infrastructure



Blue chip client list

- ~400 active clients
- Partnering with large / mid-size / emerging biopharma and other industries
- Clients concentrated in US, Europe & Japan
- Track record of working with diverse industry sectors



Making a difference

- Partnerships have delivered numerous clinical candidates
- Delivery history for integrated CMC programs up to clinical trials and beyond



Experienced workforce: building capabilities and careers

8,373 total headcount

5,778 scientists delivering high quality solutions – create a competitive edge

7% PHDs

Inspiring technical excellence and providing opportunities to grow

Empowering our workforce

- **Thrive360 operating philosophy** embedding wellbeing into how work is designed and delivered - supporting physical, mental & emotional, social, financial and career wellbeing
- **Future-focused performance and career conversations** that build capability, clarify growth pathways and strengthen engagement and retention

Continuous learning & development

- **Enterprise-wide leadership and manager capability development** to build strong people leadership and succession depth
- **Scientific skills development** to standardise and advance scientific and technical upskilling across the organization
- Supporting **talent stability and execution** continuity during a demanding operating environment

Shaping a culture of belonging

- **Inclusive culture** broadening access to scientific and leadership talent
- **Diverse teams** strengthening innovation and problem-solving
- **27%** women representation overall and **19%** women in senior management

All figures are as on March 31, 2026

Extended our state-of-the-art infrastructure & new capabilities with global presence to meet our strategic partners needs

HQ campus at Bangalore, India

where most of Syngene's capabilities are housed today



Biologics

Discovery development & and manufacturing plants in Bangalore, India

Fully functional R&D Centre at

Genome Valley, Hyderabad, India



API manufacturing


Commercial manufacturing to support product launch located at Mangalore, India

USA based Biologics facility

Bayview, Baltimore, USA



We currently operate a range of successful collaboration models




Dedicated R&D Labs

- Customers receive ring-fenced infrastructure customized to their research needs
- Dedicated scientific and support teams work exclusively on the customer's projects
- Long-term strategic partnerships, typically extending for five years or more, foster deep collaboration and sustained innovation



Full time equivalent (FTE)

- A dedicated team of scientific personnel from predefined disciplines works exclusively on the customer's projects
- Deliverables and team composition evolve as the project progresses to align with changing requirements
- Agreements are typically renewed annually, ensuring continuity and flexibility



Fee For service (FFS)

- Services are provided within a defined scope
- Flexible, on-demand personnel and research infrastructure are allocated to meet project objectives
- Engagements can be short-term or long-term, based on project requirements



Risk / Reward Model

- A milestone-driven approach covering a portfolio of research projects
- Customers benefit from reduced upfront costs, with payments tied to predefined success milestones




Outcome – based model with Service Level Agreement

- A contract structured around the achievement of predefined outcomes
- Linked to specific productivity goals to ensure performance-driven results

... and are open to any single or combination of above

Our experience spans multiple industry segments and partners us with global leaders across the world...



Operational robustness driving strategy execution

Continuous improvement embedded through a structured Lean Six Sigma framework


Certification pathway from White Belt to Master Black Belt
90+ Green Belts and 60+ Black Belts driving operational excellence
10+ Master Black Belts anchoring enterprise-level transformation

Quality management system: digitized and audit-ready

85 customer and regulator audits in the last FY
6 successful USFDA audits in the last 5 years

Client-focused commercial organization

Leaders based in the US, Europe, UK and Asia
close to client locations



Focused execution through strong Project Management

Structured program management for executing client projects enabled by SynPro platform and SynPro Academy ensuring delivery of client projects

Digital as a differentiator

AI capability in all research teams
Integrating automation, IT solutions, and data analytics, we optimize workflows, enhance resource allocation and utilization, and ensure regulatory compliance

Strategic Sourcing that makes a difference

Effective global collaboration with 2,800+ suppliers across 30 countries

Building a resilient supply chain amid geopolitical uncertainty through robust logistics network, dual sourcing strategy, and domestic supplier development for critical raw materials.

Syngene digital initiatives aimed at driving innovation and operational

At Syngene, IT strategy is closely aligned with organizational priorities, emphasizing investments in automation and digitization to improve scientific and enterprise functions.

Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements


Initiatives to automate and integrate core business processes, enhancing Syngene's digital presence and customer engagement.

"Fail fast" approach to AI and GenAI, launching small-scale pilots to quickly test feasibility, assess early outcome

Comprehensive 1-3-5-year roadmap to future-proof operations and build next-generation digital capabilities, with an emphasis on AI adoption

Automate workflows, eliminate errors, and improve execution quality

Advanced IT and cybersecurity landscape with a One-Click Disaster Recovery system, CDC & ISWG



Committed to safety and sustainability

Safety is our first priority

- Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures
- Risk assessments are an integral part of our operation
- Kavach, our flagship safety program, has delivered improvement in safety metrics and drives focus on industrial safety for all employees
- Lost time injury frequency rate (LTIFR): 0.03
- 35,365 hours of EHSS training



Proud to be recognized by TIME Magazine and Statista as:

- **World's Most Sustainable Companies 2025**
- **World's Best Companies in Sustainable Growth 2026**
- **World's Most Sustainable Companies 2026**

Committed to environmental protection

- Achieved 61% reduction of SBTi Scope 1 & 2 emissions, exceeding target of 54.6%
- 95% of energy procured from renewable energy sources
- 73,741 tCO2e of GHG emissions avoided
- ISO 50001:2018 Energy Management Certificate for Bengaluru & Mangaluru
- 97% of total hazardous and non-hazardous waste recycled
- Zero waste to direct landfill
- 58% YoY freshwater savings achieved
- 1,14,633 KL fresh water saved from recycling, reusing and rainwater harvesting
- 2,231 KL rainwater harvested

ESG Rating Performance

ESG Rating Agency

EcoVadis

FY25

Silver (91st percentile)

FY24

Silver (86th percentile)

FY23

Bronze (65th percentile)

CDP

B (Water Security)
B (Climate Change)

B (Water Security)
B (Climate Change)

D (Water Security)
C (Climate Change)

Sustainalytics

14.7 Low Risk

15.6 Low Risk

12.4 Low Risk

MSCI

A

BB

BBB

DJSI

76

50

N/A

Accreditations



- USFDA, EMA, UK VMD, PMDA and Health Canada Certified GMP facilities.
- GLP, NABL (ISO IEC 17025) certification for Safety Assessment and Large Molecule Bioanalytical Laboratory
- GLP certification for Viral Testing Facility, AAALAC Accreditation and CCSEA registration for Safety Assessment
- USFDA, MHRA. AGES inspected & ANVISA approved Translational and Clinical research facility
- ISO 15189:2012, NABL & College of American Pathologists (CAP) accredited Clinical and Molecular diagnostics facility
- ISO 9001:2015, 14001:2015, 45001:2018, ISO 13485:2016, ISO 50001:2018 and ISO/IEC 27001:2022 accreditations.



We have consistently received industry recognition for our scientific capability and business excellence

- **CMO Leadership Awards 2022** Presented by Life Science Leader and Outsourced Pharma
- **CMO Leadership Award Champion 2022** - Presented by Life Science Leader and Outsourced Pharma
- **Golden Peacock Award for Excellence in Corporate Governance** for 2021 by the Institute of Directors at the 'Golden Peacock Awards Ceremony'
- **The 2022 Brandon Hall Group HCM Excellence Bronze Award** In Leadership Development for 'Best Unique or Innovative Leadership Program' and 'Best Advance in Compliance Training'
- **The 2022 Brandon Hall Group HCM Excellence Bronze Award** In Leadership Development for
- **Asia Pacific Biologics CMO Excellence Awards 2022** - For Quality
- **Biopharma Honours Award 2022** - For Viral Testing Facility by Informa Markets
- **Most Preferred Workplace 2022** - Award by MarksmenDaily.com

- **EcoVadis Sustainability Rating, 2024** : Syngene secured silver rating in the EcoVadis sustainability index for commitment to ESG practices and ranked among the top 15% of companies assessed worldwide.
- **Asia Pacific Biologics CMO Excellence Awards 2024** : Adjudged Best Biologics CMO in South Asia by IMAPAC
- Winner under the Reliability and Compatibility categories for exceeding customer expectations at **CDMO Leadership Awards 2024**
- Declared champion by the Institute of Supply Chain Management (ISCM) at the **Pharma Supply Chain Management 5.0 summit**.
- Award for Excellence in Environment Health and Safety (EHS) practices at **CII-SR EHS Excellence Awards 2023**
- Awarded **India's Best Managed Company** by Deloitte
- **Golden Peacock Award 2023**: For risk management practices under the Pharmaceutical sector category.
- **Best Overall Sustainable Performance (Pharmaceutical) 2023** at the 2nd Edition India Sustainability Conclave & Awards 2023



2021

2022

2023

2024

2025-2026

- **Dream Companies to Work Award** at the 29th Edition of the World HRD Congress Awards.
- **Asian Leadership Award for Excellence in Branding and Marketing** in the Contract Research Development and Manufacturing category
- **CRISIL awards Syngene Top score among Indian Pharma** - for Environment Safety Governance (ESG)
- **Syngene ranked #69 in Fortune India magazine's** list of 'Top 100 Indian wealth creators 2021'
- **India Pharma Awards 2021** for Operational Excellence—Manufacturing organized by Informa Markets, India
- **Best Governed Company in the Listed Segment: Medium Category** at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI)
- **Best Corporate Foundation Award** at the World CSR Congress

- **Golden Peacock National Quality Award 2023** For meeting the overall requirements of the Golden Peacock Excellence Model
- **Biopharma Excellence Awards 2023** For Best Contract Development and Manufacturing Organization (CDMO)

- **CDMO Leadership Award 2025**: Adjudged winner in the Biologics category by Outsourced Pharma and Life Science Connect.
- **Biopharma Excellence Awards 2025 (India Edition)**: Adjudged Best Bioprocessing Supplier – Analytical Services by IMAPAC.
- **Pharma Supply Chain Champion 2025**: Ranked #1 among mid-sized pharma and API firms by the Institute of Supply Chain Management (ISCM).
- **TIME Magazine & Statista – World's Most Sustainable Companies 2026**: Ranked amongst the global top three and #1 in India in the Pharma & Biotech category; second recognition in six months.
- **S&P Global Sustainability Yearbook 2026**: Ranked among the top 10 life sciences companies and the top 9% globally; recognised as an 'Industry Mover' for achieving the highest year-on-year improvement in its Corporate Sustainability Assessment score.
- **NAMC Gold Award**: Biologics Manufacturing Excellence at the National Awards for Manufacturing Competitiveness (NAMC).
- **Achieved My Green Lab 'Green Certification' (>94% score)** for laboratories
- **EcoVadis 2025 score** improved to 74/100, placing Syngene in the 91st percentile globally.

Syngene has established an enterprise-wide risk oversight with clear accountability from management to the Board

Syngene’s enterprise-wide risk management framework provides a holistic approach to identification, monitoring, reporting and mitigating risks that could impact performance



4

Financials



Q2 FY27 financial highlights

All figures in Rs. Cr unless otherwise specified

Particulars	Q2 FY27	Q1FY27	Q2 FY26	QoQ change	YoY change
Revenue from operations	833	736	911	13%	-9%
Other income	28	25	15	10%	82%
Reported revenue	861	761	926	13%	-7%
Material costs	199	173	239	15%	-17%
Staff costs	280	281	307	0%	-9%
Other direct costs	29	30	25	-2%	17%
Other expenses	116	110	128	5%	-10%
Foreign exchange (gain)/loss, net	61	50	12	23%	421%
EBITDA	175	116	215	51%	-18%
EBITDA Margin	20%	15%	23%		
Operating EBITDA (ex-other income)	147	91	200	63%	-26%
Operating EBITDA Margin	18%	12%	22%		
Depreciation and Finance Cost	112	112	117	0%	-4%
PBT	54	-6	85	n/m	-37%
Tax	16	-7	18	n/m	-12%
PAT before exceptional items	38⁽¹⁾	1⁽¹⁾	67	37x	-44%
PAT after exceptional items	32	-9	67	n/m	-52%

(1) Excludes expenses recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy: Rs 6 Cr (net of tax) in Q2 FY27 and Rs 10 Cr (net of tax) in Q1 FY27

(2) Other Net Assets calculated as all assets other than cash and cash equivalents less all liabilities other than debt and shareholders equity

(3) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year

Balance Sheet Highlights

As on 30th September 2026

All figures in Rs. Cr unless otherwise specified

Shareholders' funds	4,859
Net Fixed assets	4,021
Other net assets ⁽²⁾	-554
Net cash/(debt) ⁽³⁾	1,392
Total Use of Funds	4,859

FY26 financial highlights

All figures in Rs. Cr unless otherwise specified

Particulars	FY26	FY25	YoY change
Revenue from operations	3,739	3,642	3%
Other income	71	71.8	-1%
Reported revenue	3,809	3,714	3%
Material costs	919	943	-3%
Staff costs	1,230	1,079	14%
Other direct costs	103	97	6%
Other expenses	508	480	6%
Foreign exchange (gain)/loss, net	61	2	3104%
EBITDA	989	1,114	-11%
EBITDA Margin	26%	30%	
Operating EBITDA (ex-other income)	918	1,042	-12%
Operating EBITDA Margin	25%	29%	
Depreciation and Finance Cost	453	433	5%
PBT	488	628	-22%
Tax	108	153	-30%
PAT before exceptional items	380⁽¹⁾	475⁽²⁾	-20%
PAT Margin	10.0%	12.8%	
PAT after exceptional items	317	496	-36%

(1) Excludes (i) impact of Rs. 38 Cr. (net of tax) pertaining to the net increase in gratuity liabilities on account of newly implemented labour codes, and (ii) expenses of Rs 25 Cr. (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy.

(2) Excludes an exceptional item of Rs 21 Cr. (net of tax) relating to the final settlement from an insurance claim.

(3) Other Net Assets calculated as all assets other than cash and cash equivalents less all liabilities other than debt and shareholders equity

(4) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year

Balance Sheet Highlights

As on 31st March 2026

All figures in Rs. Cr unless otherwise specified

Shareholders' funds	4,839
Net Fixed assets	4,046
Other net assets ⁽³⁾	-1,007
Net cash/(debt) ⁽⁴⁾	1,800
Total Use of Funds	4,839

5

Shareholding and Share Information



Syngene and Biocon Group

Syngene

Syngene is an operationally independent publicly listed subsidiary of Biocon Limited, established in 1993 as India's first Contract Research Organization. The Company has 30+ years of experience in novel molecule discovery, development and manufacturing services




Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company and has majority holding in key operating entities including Syngene

Syngene

Integrated services:

- Research Services
- Development and for
- Manufacturing small/large molecules




- Product Based
- Biosimilars
- Formulations and Compounds
- Alternative Therapeutic Drugs



Shareholding and Share Information

Syngene's shareholding*



Syngene's Share Information*

NSE Ticker	SYNGENE
BSE Ticker	539268
Market Cap (Rs. Cr)	14,382
% free-float^	47%
Free-float market cap (Rs. Cr)	6818
Share Outstanding (Cr)	40

• As on 30th September 2026
• ^ Free float includes shares held by public and in ESOP Trust

For more details

Visit our website www.syngeneintl.com



<https://www.linkedin.com/company/syngene-international-limited>



<https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ>

IR Contact:

Soudabi Neduvanchery

investor@syngeneintl.com

soudabi.neduvanchery1@syngeneintl.com

Media Contact:

Vijay Jeevanandham

E: _Vijay.jeevanandham@syngeneintl.com

